Ascendis Pharma Earnings Estimate

ASND Stock  USD 222.03  0.12  0.05%   
By analyzing Ascendis Pharma's earnings estimates, investors can diagnose different trends across Ascendis Pharma's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Ascendis Pharma AS is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Embargo
 
Inflation
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Ascendis Pharma is projected to generate 1.010525 in earnings per share on the 31st of December 2026. Ascendis Pharma earnings estimates show analyst consensus about projected Ascendis Pharma AS EPS (Earning Per Share). It derives the highest and the lowest estimates based on Ascendis Pharma's historical volatility. Many public companies, such as Ascendis Pharma, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Ascendis Pharma's earnings estimates, investors can diagnose different trends across Ascendis Pharma's analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 385.7 M, whereas Pretax Profit Margin is forecasted to decline to (1.24). Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Ascendis Pharma Earnings per Share Projection vs Actual

About Ascendis Pharma Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Ascendis Pharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Ascendis Pharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Ascendis Pharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-2.3 B-2.2 B
Earnings Yield(0.06)(0.06)
Price Earnings Ratio(23.41)(22.24)
Price Earnings To Growth Ratio 0.78  0.81 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Ascendis diversify its offerings? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ascendis Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(4.52)
Revenue Per Share
10.729
Quarterly Revenue Growth
2.694
Return On Assets
(0.08)
Return On Equity
(8.18)
Understanding Ascendis Pharma AS requires distinguishing between market price and book value, where the latter reflects Ascendis's accounting equity. The concept of intrinsic value - what Ascendis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Ascendis Pharma's price substantially above or below its fundamental value.
Understanding that Ascendis Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascendis Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Ascendis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.